{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:55:55Z","timestamp":1781510155547,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jgar.2025.12.013","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:02:31Z","timestamp":1766448151000},"page":"241-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical outcome comparison between adjunctive clindamycin vs. linezolid for invasive group A streptococcal infection"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7984-493X","authenticated-orcid":false,"given":"Eriko","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taito","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.12.013_bib0001","unstructured":"Centers for Disease Control and Prevention. Clinical guidance for Streptococcal Toxic Shock Syndrome. 2025. https:\/\/www.cdc.gov\/group-a-strep\/hcp\/clinical-guidance\/streptococcal-toxic-shock-syndrome.html. Accessed November 26, 2025."},{"key":"10.1016\/j.jgar.2025.12.013_bib0002","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2165\/11634180-000000000-00000","article-title":"Invasive group a streptococcal disease: epidemiology, pathogenesis and management","volume":"72","author":"Steer","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2025.12.013_bib0003","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.12.013_bib0004","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S1473-3099(20)30523-5","article-title":"Effectiveness of adjunctive clindamycin in \u03b2-lactam antibiotic-treated patients with invasive \u03b2-haemolytic streptococcal infections in US hospitals: a retrospective multicentre cohort study","volume":"21","author":"Babiker","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.12.013_bib0005","unstructured":"US Centers for Disease Control and Prevention, ABCs Bact Facts interactive data dashboard: group A Streptococcus, https:\/\/www.cdc.gov\/abcs\/bact-facts\/data-dashboard.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/abcs\/bact-facts-interactive-dashboard.html, 2021. Accessed September 1, 2025."},{"key":"10.1016\/j.jgar.2025.12.013_bib0006","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S1473-3099(24)00507-3","article-title":"Adjunctive linezolid versus clindamycin for toxin inhibition in \u03b2-lactam-treated patients with invasive group A streptococcal infections in 195 US hospitals from 2016 to 2021: retrospective cohort study with target trial emulation","volume":"25","author":"Babiker","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.12.013_bib0007","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/cid\/ciac720","article-title":"Should linezolid replace clindamycin as the adjunctive antimicrobial of choice in group A streptococcal necrotizing soft tissue infection and toxic shock syndrome? A focused debate","volume":"76","author":"Cort\u00e9s-Penfield","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.12.013_bib0008","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/cid\/ciaa027","article-title":"Risk factors and predictors of mortality in streptococcal necrotizing soft-tissue infections: a multicenter prospective study","volume":"72","author":"Bruun","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.12.013_bib0009","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/cid\/ciy401","article-title":"Polyspecific intravenous immunoglobulin in clindamycin-treated patients with Streptococcal Toxic Shock Syndrome: a systematic review and meta-analysis","volume":"67","author":"Parks","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.12.013_bib0010","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1093\/cid\/ciy401","article-title":"Polyspecific intravenous immunoglobulin in clindamycin-treated patients with Streptococcal Toxic Shock Syndrome: a systematic review and meta-analysis","volume":"67","author":"Parks","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.12.013_bib0011","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/dkl173","article-title":"Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation","volume":"58","author":"Sriskandan","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2025.12.013_bib0012","unstructured":"World Health Organization. Disease Outbreak News increased incidence of scarlet fever and invasive group A Streptococcus infection\u2014multi-country. https:\/\/www.who.int\/emergencies\/disease-outbreak-news\/item\/2022-DON429. 2022. Accessed September 1, 2025."},{"key":"10.1016\/j.jgar.2025.12.013_bib0013","unstructured":"World Health Organization. Increase in invasive group A streptococcal infections among children in Europe, including fatalities. 2022. Available at: https:\/\/www.who.int\/europe\/news\/item\/12-12-2022-increase-in-invasive-group-a-streptococcal-infections-among-children-in-europe\u2013including-fatalities. Accessed November 26, 2025."},{"key":"10.1016\/j.jgar.2025.12.013_bib0014","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3390\/pathogens13111007","article-title":"Group A Streptococcus infections in children: epidemiological insights before and after the COVID-19 pandemic","volume":"13","author":"Karapati","year":"2024","journal-title":"Pathogens"},{"key":"10.1016\/j.jgar.2025.12.013_bib0015","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.1097\/INF.0000000000003195","article-title":"The indirect impact of the SARS-CoV-2 pandemic on invasive group a Streptococcus, Streptococcus pneumoniae and Staphylococcus aureus infections in Houston Area children","volume":"40","author":"McNeil","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2025.12.013_bib0016","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S2352-4642(23)00295-X","article-title":"Invasive group A streptococcal infections in children and adolescents in Denmark during 2022-23 compared with 2016-17 to 2021-22: a nationwide, multicentre, population-based cohort study","volume":"8","author":"Nygaard","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.jgar.2025.12.013_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00729-23","article-title":"Clinical, microbiological, and molecular characterization of pediatric invasive infections by Streptococcus pyogenes in Spain in a context of global outbreak","volume":"9","author":"Ram\u00edrez de Arellano","year":"2024","journal-title":"mSphere"},{"key":"10.1016\/j.jgar.2025.12.013_bib0018","unstructured":"Centers for Disease Control and Prevention. Streptococcus disease, invasive, group a (Streptococcus pyogenes) 1995 case definition. Accessed December 7, 2025. https:\/\/ndc.services.cdc.gov\/case-definitions\/streptococcus-disease-invasive-group-a-1995\/."},{"key":"10.1016\/j.jgar.2025.12.013_bib0019","unstructured":"Centers for Disease Control and Prevention. Group A strep (GAS): about GAS. 2023. Accessed December 7, 2025. https:\/\/www.cdc.gov\/group-a-strep\/about\/index.html#cdc_disease_basics_risk-risk-factors-for-serious-infections."},{"key":"10.1016\/j.jgar.2025.12.013_bib0020","unstructured":"Centers for Disease Control and Prevention. Streptococcal Toxic-Shock Syndrome 2010 case definition. Accessed December 7, 2025. https:\/\/ndc.services.cdc.gov\/case-definitions\/streptococcal-toxic-shock-syndrome-2010\/."},{"key":"10.1016\/j.jgar.2025.12.013_bib0021","doi-asserted-by":"crossref","first-page":"24","DOI":"10.71079\/ASIDE.IM.03222516","article-title":"TriNetX and real-world evidence: a critical review of its strengths, limitations, and bias considerations in clinical research","volume":"1","author":"Nassar","year":"2025","journal-title":"ASIDE Intern Med"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002814?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525002814?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:47:19Z","timestamp":1781509639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525002814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"alternative-id":["S2213716525002814"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.12.013","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical outcome comparison between adjunctive clindamycin vs. linezolid for invasive group A streptococcal infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}